Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.25 -2.63%

-$0.25 today

Market cap
$1.58B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 3.48M

Average 1.76M

VIR Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Vir Biotechnology, Inc.NASDAQ: VIR

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to 433431.0%

Net margin was 433431.0% in Q1 FY2026, up 437420.6 pp from a year earlier. On a trailing-twelve-month basis it was -676.0%, up 2093.1 pp year over year. Over 3 fiscal years it narrowed by 670.8 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 6 analysts of -54.2% for the fiscal year ending Dec 2026, up from -638.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
433431.0%+433498.0 pp QoQ
Last fiscal yearDec 2025
-638.9%+64.5 pp YoY
LTMMar 2026
-676.0%+2093.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+437420.6 pp+9181.3 pp-428239.3 pp
1 year+64.5 pp+584.7 pp+520.2 pp
3 years-670.8 pp+301.0 pp+971.8 pp
5 years+598.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-638.9%
Year-over-year change
+64.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VIR compares with its peers on the latest reported figures

  • VIR's LTM Mar 2026 net margin of -676.0% is the lowest of the 9 companies compared; the peer median is -52.5%.
  • Its year-over-year change of +2093.1 pp is the highest of 9, against a peer median of -2.3 pp.
  • Over three fiscal years its change of -670.8 pp compares with a peer median of -26.3 pp.
VIR Competitors Peer median
Net Margin for VIR and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 202684.0% +1279.8 pp-59.9 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-9.0% +115.2 pp—
NVAXNovavax, Inc.LTM Mar 2026-14.7% -52.9 pp+80.3 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-40.9% -34.5 pp+121.4 pp
BNTXBioNTech SELTM Jun 2026-64.0% -52.0 pp-94.1 pp
VALNValneva SELTM Mar 2026-88.3% -45.1 pp-26.3 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-89.6% +60.0 pp+16.0 pp
MRNAModerna, Inc.LTM Sep 2026-110.5% +29.8 pp-189.5 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-676.0% +2093.1 pp-670.8 pp
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding VIR) -52.5%-2.3 pp-26.3 pp

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.